ARC as a Regulatory Signal Rare disease drug development often requires sponsors to generate persuasive evidence in small, heterogeneous populations where natural history is limited, endpoints may lack precedent, and conventional trial designs may not be feasible. To address these systemic bottlenecks, FDA launched the Accelerating Rare Disease Cures Program, or ARC, through CDER in [...]